Giuseppe Derosa1, Pamela Maffioli2, Amirhossein Sahebkar3. 1. Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy; Center for the Study of Endocrine-Metabolic Pathophysiology and Clinical Research, University of Pavia, Italy; Molecular Medicine Laboratory, University of Pavia, Pavia, Italy. 2. Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy; PhD School in Experimental Medicine, University of Pavia, Pavia, Italy. 3. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. Electronic address: amir_saheb2000@yahoo.com.
Abstract
BACKGROUND: Hyperuricaemia increases the risk of gout, but it is also a risk factor for cardiovascular diseases. PURPOSE: To conduct a systematic review and meta-analysis of relevant randomized clinical trials to ascertain the effect size of fibrates in modulating plasma uric acid concentrations. DATA SOURCES: Medline (http://www.ncbi.nlm.nih.gov/pubmed), SCOPUS, Web of Science and Google Scholar databases were searched. STUDY SELECTION: Studies were included if they met the following inclusion criteria: (i) being a randomized placebo-controlled trial with either parallel or cross-over design, (ii) investigating the impact of fibrate therapy on plasma uric acid concentrations, (iii) presentation of sufficient information on uric acid values at baseline and at the end of follow-up in each group or providing the net change values. DATA EXTRACTION: The following data were extracted: (1) first author's name; (2) year of publication; (3) study location; (4) study design; (5) number of participants in the fibrate and placebo groups; (6) type and dose of fibrate; (7) duration of treatment; (8) age, gender and body mass index (BMI) of study participants; (9) baseline levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, high-sensitivity C-reactive protein (hs-CRP) and glucose; (10) systolic and diastolic blood pressure; and (11) data regarding baseline and follow-up uric acid. DATA SYNTHESIS: There was a significant reduction in plasma uric acid concentrations following fenofibrate therapy. LIMITATIONS: Few eligible studies, and most had small population sizes. CONCLUSIONS: Fenofibrate, but not bezafibrate is effective in reducing serum acid uric levels.
BACKGROUND:Hyperuricaemia increases the risk of gout, but it is also a risk factor for cardiovascular diseases. PURPOSE: To conduct a systematic review and meta-analysis of relevant randomized clinical trials to ascertain the effect size of fibrates in modulating plasma uric acid concentrations. DATA SOURCES: Medline (http://www.ncbi.nlm.nih.gov/pubmed), SCOPUS, Web of Science and Google Scholar databases were searched. STUDY SELECTION: Studies were included if they met the following inclusion criteria: (i) being a randomized placebo-controlled trial with either parallel or cross-over design, (ii) investigating the impact of fibrate therapy on plasma uric acid concentrations, (iii) presentation of sufficient information on uric acid values at baseline and at the end of follow-up in each group or providing the net change values. DATA EXTRACTION: The following data were extracted: (1) first author's name; (2) year of publication; (3) study location; (4) study design; (5) number of participants in the fibrate and placebo groups; (6) type and dose of fibrate; (7) duration of treatment; (8) age, gender and body mass index (BMI) of study participants; (9) baseline levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, high-sensitivity C-reactive protein (hs-CRP) and glucose; (10) systolic and diastolic blood pressure; and (11) data regarding baseline and follow-up uric acid. DATA SYNTHESIS: There was a significant reduction in plasma uric acid concentrations following fenofibrate therapy. LIMITATIONS: Few eligible studies, and most had small population sizes. CONCLUSIONS:Fenofibrate, but not bezafibrate is effective in reducing serum acid uric levels.
Authors: Roberto Ferrari; Carlos Aguiar; Eduardo Alegria; Riccardo C Bonadonna; Francesco Cosentino; Moses Elisaf; Michel Farnier; Jean Ferrières; Pasquale Perrone Filardi; Nicolae Hancu; Meral Kayikcioglu; Alberto Mello E Silva; Jesus Millan; Željko Reiner; Lale Tokgozoglu; Paul Valensi; Margus Viigimaa; Michal Vrablik; Alberto Zambon; José Luis Zamorano; Alberico L Catapano Journal: Eur Heart J Suppl Date: 2016-04-12 Impact factor: 1.803
Authors: Jeffrey N Miner; Philip K Tan; David Hyndman; Sha Liu; Cory Iverson; Payal Nanavati; David T Hagerty; Kimberly Manhard; Zancong Shen; Jean-Luc Girardet; Li-Tain Yeh; Robert Terkeltaub; Barry Quart Journal: Arthritis Res Ther Date: 2016-10-03 Impact factor: 5.156
Authors: Maria Dolores Sanchez-Niño; Binbin Zheng-Lin; Lara Valiño-Rivas; Ana Belen Sanz; Adrian Mario Ramos; Jose Luño; Marian Goicoechea; Alberto Ortiz Journal: Clin Kidney J Date: 2017-05-26